ClinicalTrials.gg
CompletedNCT05505916Updated Jun 5, 2026

An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)

A Phase 3 interventional study of KVD900 600 mg and KVD900 300 mg in Hereditary Angioedema, sponsored by KalVista Pharmaceuticals, Ltd.. Completed at 71 sites in 23 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-06-05.

Sponsored by KalVista Pharmaceuticals, Ltd. (part of Chiesi Farmaceutici S.p.A.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
145
Allocation
Non-randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Angioedemas, Hereditary by Chiesi Farmaceutici S.p.A. — 1 open to participants now, 1 under way, none of them phase 3. Angioedemas, Hereditary · Chiesi Farmaceutici S.p.A..

Started
2022
with 2 others
Phase 3
4 of 12
none open now
Registered
6th of 12
by date

Among the 12 studies in Angioedemas, Hereditary by Chiesi Farmaceutici S.p.A., this one is one of 3 that started in 2022, is one of 4 in phase 3, and was the 6th registered.

Angioedemas, Hereditary

171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.

Browse Angioedemas, Hereditary studies →

Open to participants now

1 of the 12 studies in Angioedemas, Hereditary by Chiesi Farmaceutici S.p.A. is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Angioedemas, Hereditary by Chiesi Farmaceutici S.p.A., or all of them as a file.
02

Study summary

This is an open-label, multicenter extension trial to evaluate the long-term safety of KVD900 in patients who are 12 years or older with HAE type I or II.

03

Conditions studied

  • Hereditary Angioedema

Keywords

  • KONFIDENT-S
  • Sebetralstat
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Patients may roll over from KVD900-301.

Inclusion criteria

Inclusion Criteria:

  1. Confirmed diagnosis of HAE type I or II at any time in the medical history
  2. Patient has had at least 2 documented HAE attacks within 3 months prior to the Enrollment Visit.
  3. If a patient is receiving long-term prophylactic treatment with one of the protocol-allowed therapies, they must have been on a stable dose and regimen for at least 3 months prior to the Enrollment Visit (except for danazol, which requires a stable dose and regimen for at least 6 months prior to the Enrollment Visit).
  4. Male or female patients 12 years of age and older.
  5. Patients must meet the requirements.
  6. Patients must be able to swallow trial tablets whole.
  7. Patients, as assessed by the Investigator, must be able to appropriately receive and store IMP, and be able to read, understand, and complete the eDiary.
  8. Investigator believes that the patient is willing and able to adhere to all protocol requirements.
  9. Patient provides signed or assent (when applicable). A parent or legally authorized representative (LAR) must also provide signed informed consent when required.

Exclusion criteria

Exclusion Criteria:

  1. Discontinued from the KVD900-301 trial for reasons of noncompliance, withdrawal of consent, or safety.
  2. Presence of any safety concerns that would preclude participation in the open-label trial as determined by the investigator.
  3. Any concomitant diagnosis of another form of chronic angioedema, such as acquired C1 inhibitor deficiency, HAE with normal C1-INH (previously known as HAE type III), idiopathic angioedema, or angioedema associated with urticaria.
  4. A history of poor response to bradykinin receptor 2 (BR2) blocker, C1-INH therapy, or plasma kallikrein inhibitor therapy for the management of HAE, in the opinion of the Investigator.
  5. Use of attenuated androgens other than danazol (e.g., stanozolol, oxandrolone, methyltestosterone, testosterone), or anti-fibrinolytics (e.g., tranexamicacid) within 28 days prior to the Enrollment Visit.
  6. Use of Angiotensin-converting enzyme (ACE) inhibitors within 7 days prior to the Enrollment Visit.
  7. Any estrogen-containing medications with systemic absorption (such as oral including ethinylestradiol or hormonal replacement therapy) within 7 days prior to the Enrollment Visit.
  8. Inadequate organ function, including but not limited to:

    1. (ALT) >2x Upper Limit Normal ()
    2. Aspartate aminotransferase (AST) >2x ULN
    3. direct >1.25x ULN
    4. (INR) >1.2
    5. Clinically significant hepatic impairment defined as a B or C
  9. Any clinically significant comorbidity or systemic dysfunction, which in the opinion of the Investigator, would jeopardize the safety of the patient by participating in the trial.
  10. History of substance abuse or dependence that would interfere with the completion of the trial, as determined by the Investigator.
  11. Known to KVD900 or to any of the .
  12. Participation in any gene therapy treatment or trial for HAE.
  13. Participation in any interventional clinical trial, including an investigational COVID-19 vaccine trial, within 4 weeks of the last dosing of investigational drug prior to the Enrollment Visit.
  14. Any pregnant or breastfeeding patient.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
145 participants (actual)

Study arms

  • Experimental
    KVD900 600 mg

    Drug: KVD900 600 mg

  • Experimental
    KVD900 300 mg

    Drug: KVD900 300 mg

Interventions

06

What researchers measure

Primary outcomes

  1. Frequencies and percentages of patients with AEs, AEs within 2 days of IMP administration, serious AE's and AEs causing premature discontinuation.

    Time frame: AEs will be recorded from the first dose of IMP in the KVD900-302 trial up to and including the end of study (EOS) visit, a maximum of 2 years for each patient.

  2. Number and percentage of patients with normal or abnormal laboratory results at each scheduled visit.

    Time frame: Throughout the duration of the trial.

  3. Number and percentage of patients with normal or abnormal vital sign results at each scheduled visit

    Time frame: Throughout the duration of the trial.

Secondary outcomes

  1. Patient Global Impression of Change (PGI-C).

    time to beginning of symptom relief defined as at least '' a little better'' (2 time points in a row)

    Time frame: within 12 hours of initial dose of IMP administration.

  2. Patient Global Impression of Severity (PGI-S): time to first incidence of 2 time points in a row decrease from baseline

    Time frame: within 12 hours of initial dose of IMP administration.

  3. PGI-S: time to HAE attack resolution

    PGI-S: time to HAE attack resolution, defines as ''none''

    Time frame: within 24 hours of initial dose of IMP administration.

07

Study locations

71 sites
  • KalVista Investigative Site
    Scottsdale, Arizona 85251, United States
  • KalVista Investigative Site
    Little Rock, Arkansas 72205, United States
  • KalVista Investigative Site
    San Diego, California 92122, United States
  • KalVista Investigative Site
    San Diego, California 92123, United States
  • KalVista Investigative Site
    Santa Monica, California 90404, United States
  • KalVista Investigative Site
    Centennial, Colorado 80112, United States
  • KalVista Investigative Site
    Colorado Springs, Colorado 80907, United States
  • KalVista Investigative Site
    Evansville, Indiana 47715, United States
  • KalVista Investigative Site
    Overland Park, Kansas 66211, United States
  • KalVista Investigative Site
    Louisville, Kentucky 40215, United States
  • KalVista Investigative Site
    Chevy Chase, Maryland 20815, United States
  • KalVista Investigative Site
    Plymouth, Minnesota 55446, United States
  • KalVista Investigative Site
    St Louis, Missouri 63141, United States
  • KalVista Investigative Site
    Charlotte, North Carolina 28277, United States
  • KalVista Investigative Site
    Cincinnati, Ohio 45236, United States
  • KalVista Investigative Site
    Toledo, Ohio 43617, United States
  • KalVista Investigative Site
    Hershey, Pennsylvania 17033, United States
  • KalVista Investigative Site
    Dallas, Texas 75231, United States
  • KalVista Investgative Site
    Layton, Utah 84041, United States
  • KalVista Investigative Site
    Spokane, Washington 99204, United States
  • KalVista Investigative Site
    Campbelltown, 2560, Australia
  • KalVista Investigative Site
    Wein, 1090, Austria
  • KalVista Investigative Site
    Sofia, 1431, Bulgaria
  • KalVista Investigative Site
    Montreal, H2W 1R7, Canada
  • KalVista Investigative Site
    Grenoble, 38043, France
  • KalVista Investigative Site
    Lille, 59037, France
  • KalVista Investigative Site
    Paris, 75012, France
  • KalVista Investigative Site
    Berlin, 12203, Germany
  • KalVista Investigative Site
    Frankfurt, 60590, Germany
  • KalVista Investigative Site
    Mainz, 55131, Germany
  • KalVista Investigative Site
    Mörfelden-Walldorf, 64546, Germany
  • KalVista Investigative Site
    Athens, 11521, Greece
  • KalVista Investigative Site
    Athens, 11527, Greece
  • KalVista Investigative Site
    Budapest, 1088, Hungary
  • KalVista Investigative Site
    Haifa, 31048, Israel
  • KalVista Investigative Site
    Petach Tikvah, 4920235, Israel
  • KalVista Investigative Site
    Ramat Gan, 52621, Israel
  • KalVista Investigative Site
    Tel Aviv, 64239, Israel
  • KalVista Investigative Site
    Padova, 35128, Italy
  • KalVista Investigative Site
    Palermo, 90146, Italy
  • KalVista Investigative Site
    Roma, 00133, Italy
  • KalVista Investigative Site
    San Donato Milanese, 20097, Italy
  • KalVista Investigative Site
    Sapporo, Hokkaido 002-8072, Japan
  • KalVista Investigative Site
    Chiba, 260-8677, Japan
  • KalVista Investigative Site
    Hiroshima, 730-8518, Japan
  • KalVista Investigative Site
    Kawagoe-shi, 350-8550, Japan
  • KalVista Investigative Site
    Maebashi, 371-8511, Japan
  • KalVista Investigative Site
    Soka-shi, 340-0041, Japan
  • KalVista Investigative Site
    Takatsuki-shi, 569-8686, Japan
  • KalVista Investgative Site
    Tokyo, 142-8666, Japan
  • KalVista Investigative Site
    Yokohama, 236-0004, Japan
  • KalVista Investigative Site
    Amsterdam, 1105 AZ, Netherlands
  • KalVista Investigative Site
    Auckland, 1023, New Zealand
  • KalVista Investigative Site
    Skopje, 1000, North Macedonia
  • KalVista Investigative Site
    Krakow, 31-503, Poland
  • KalVista Investigative Site
    Lodz, 92-213, Poland
  • KalVista Investigative Site
    Porto, 4200-319, Portugal
  • KalVista Investigative Site
    Sângeorgiu de Mureş, 547530, Romania
  • KalVista Investigative Site
    Riyadh, 11211, Saudi Arabia
  • KalVista Investigative Site
    Martin, 036 59, Slovakia
  • Kalvista Investigative Site
    Cape Town, 7700, South Africa
  • KalVista Investigative Site
    Barcelona, 08035, Spain
  • KalVista Investigative Site
    Barcelona, 08907, Spain
  • KalVista Investigative Site
    Madrid, 28046, Spain
  • KalVista Investigative Site
    Birmingham, B9 5SS, United Kingdom
  • KalVista Investigative Site
    Cambridge, CB2 0QQ, United Kingdom
  • KalVista Investigative Site
    Cardiff, CF14 4XW, United Kingdom
  • KalVista Investigative Site
    Frimley, GU16 7UJ, United Kingdom
  • KalVista Investigative Site
    Leeds, LS9 7TF, United Kingdom
  • KalVista Investigative Site
    London, E1 2ES, United Kingdom
  • KalVista Investigative Site
    London, NW3 2QG, United Kingdom
08

References and documents

Publications

  • Kinaciyan T, Aygoren-Pursun E, Martinez-Saguer I, Soteres DF, Honda D, Manning ME, Wedner HJ, Fukunaga A, Kanarek HJ, Ohmura K, Melamed I, El-Shanawany T, Bouillet L, Lumry WR, Riedl MA, Koleilat M, Geng B, Ohsawa I, Bara N, Rehman S, Bernstein JA, Busse PJ, Cancian M, Cohn DM, Craig TJ, Farkas H, Kiani-Alikhan S, Li HH, Raasch JP, Tachdjian R, Audhya PK, Bajcic P, Chuang YH, Iverson M, Smith MD, Yea CM, Zanichelli A. Sebetralstat for breakthrough attacks in patients with hereditary angioedema receiving long-term prophylaxis in KONFIDENT-S. J Allergy Clin Immunol Glob. 2026 Jun 12;5(5):100750. doi: 10.1016/j.jacig.2026.100750. eCollection 2026 Sep. PubMed 42436759 ↗
  • Bernstein JA, Aygoren-Pursun E, Cancian M, Cohn DM, Craig T, Grivcheva-Panovska V, Jordan A, Lumry WR, Martinez-Saguer I, Melamed I, Ohmura K, Peter J, Riedl MA, Soteres DF, Staubach P, Stobiecki M, Chuang YH, Smith MD, Yea CM, Audhya PK, Zanichelli A, Farkas H. Sebetralstat for On-Demand Treatment of Mucosal Hereditary Angioedema Attacks in KONFIDENT-S. Clin Transl Allergy. 2025 Nov;15(11):e70118. doi: 10.1002/clt2.70118. PubMed 41252457 ↗
  • Farkas H, Anderson J, Bouillet L, Caballero T, Cancian M, Craig T, Fukunaga A, Grivcheva-Panovska V, Guilarte M, Honda D, Kanarek H, Kiani-Alikhan S, Kinaciyan T, Leguevaques D, Longhurst HJ, Magerl M, Manning ME, Martinez-Saguer I, Melamed I, O'Connor ME, Peter J, Savic S, Soteres DF, Staevska M, Staubach P, Stobiecki M, Tachdjian R, Valerieva A, Yong PFK, Hao J, Iverson M, Smith MD, Yea CM, Audhya PK, Aygoren-Pursun E, Bernstein JA, Cohn DM, Lumry WR, Riedl MA, Zanichelli A, Maurer M. Long-Term Safety and Effectiveness of Sebetralstat: Interim Analysis of KONFIDENT-S Open-label Extension. J Allergy Clin Immunol Pract. 2025 Nov;13(11):3094-3103.e5. doi: 10.1016/j.jaip.2025.08.020. Epub 2025 Aug 29. PubMed 40886933 ↗

Individual participant data

Plan to share: No — Data will not be shared until all global regulatory filings are complete.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2022 to primary completion in May 2026, 43 months.

Of 46 industry-sponsored phase 3 interventional studies under Angioedemas, Hereditary, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 33. This study's 43 months is above that.

Counting every sponsor, half of 46 studies reached it within 22 months; a quarter within 16 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2022
First posted
Aug 18, 2022
StartActual
Oct 24, 2022
Primary completionActual
May 27, 2026
CompletionActual
May 27, 2026
Last update
Jun 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05505916
Responsible party
Sponsor
First posted
Aug 18, 2022
Start date
Oct 24, 2022
Primary completion
May 27, 2026
Completion
May 27, 2026
Last update
Jun 5, 2026

Study contacts

Study Director
study director · KalVista Pharmaceuticals, Ltd.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sebetralstat

Start the discussion